Patients' and donors' characteristics, conditioning, and GVHD prophylaxis
. | PBSC Group . | BM Group . |
|---|---|---|
| No. patients | 107 | 107 |
| Recipient age, y (range) | 35 (5-56) | 37 (1-55) |
| Donor age, y (range) | 33 (20-53) | 36 (18-55) |
| Sex | ||
| Recipient | ||
| No. male | 56 | 60 |
| No. female | 51 | 47 |
| Donor | ||
| No. male | 72 | 62 |
| No. female | 35 | 44 |
| Diagnoses | ||
| Acute myeloid leukemia | ||
| Early disease, no. | 12 | 11 |
| Late disease, no. | 24 | 24 |
| Acute lymphocytic leukemia | ||
| Early disease, no. | 5 | 7 |
| Late disease, no. | 11 | 10 |
| Chronic myeloid leukemia | ||
| CP, no. | 43 | 43 |
| AP, no. | 6 | 6 |
| BC, no. | 2 | 3 |
| Lymphoma, no. | 1 | 0 |
| Myelodysplastic syndrome, no. | 2 | 2 |
| Aspartylglycosaminurea, no. | 1 | 1 |
| Recipient CMV serology, (-/+) | 43/64 | 47/59 |
| Donor CMV serology (-/+) | 61/46 | 58/48 |
| Conditioning | ||
| TBI containing, no. (%) | 75 (70%) | 90 (84%) |
| Busulfan containing, no. | 31 (29%) | 17 (16%) |
| No. ATG/OKT-3 | 25/11 | 21/16 |
| GVHD prophylaxis | ||
| CsA or MTX, no. | 2 | 3 |
| CsA + prednisolone, no. | 3 | 3 |
| CsA + MMF ± pred, no. | 3 | 0 |
| CsA + MTX ± pred, no. | 96 | 100 |
| CsA + MTX ± pred + MMF, no. | 3 | 1 |
| Follow-up, y (range) | 4.4 (2.3-7.3) | 5.0 (0.7-8.4) |
. | PBSC Group . | BM Group . |
|---|---|---|
| No. patients | 107 | 107 |
| Recipient age, y (range) | 35 (5-56) | 37 (1-55) |
| Donor age, y (range) | 33 (20-53) | 36 (18-55) |
| Sex | ||
| Recipient | ||
| No. male | 56 | 60 |
| No. female | 51 | 47 |
| Donor | ||
| No. male | 72 | 62 |
| No. female | 35 | 44 |
| Diagnoses | ||
| Acute myeloid leukemia | ||
| Early disease, no. | 12 | 11 |
| Late disease, no. | 24 | 24 |
| Acute lymphocytic leukemia | ||
| Early disease, no. | 5 | 7 |
| Late disease, no. | 11 | 10 |
| Chronic myeloid leukemia | ||
| CP, no. | 43 | 43 |
| AP, no. | 6 | 6 |
| BC, no. | 2 | 3 |
| Lymphoma, no. | 1 | 0 |
| Myelodysplastic syndrome, no. | 2 | 2 |
| Aspartylglycosaminurea, no. | 1 | 1 |
| Recipient CMV serology, (-/+) | 43/64 | 47/59 |
| Donor CMV serology (-/+) | 61/46 | 58/48 |
| Conditioning | ||
| TBI containing, no. (%) | 75 (70%) | 90 (84%) |
| Busulfan containing, no. | 31 (29%) | 17 (16%) |
| No. ATG/OKT-3 | 25/11 | 21/16 |
| GVHD prophylaxis | ||
| CsA or MTX, no. | 2 | 3 |
| CsA + prednisolone, no. | 3 | 3 |
| CsA + MMF ± pred, no. | 3 | 0 |
| CsA + MTX ± pred, no. | 96 | 100 |
| CsA + MTX ± pred + MMF, no. | 3 | 1 |
| Follow-up, y (range) | 4.4 (2.3-7.3) | 5.0 (0.7-8.4) |
Absolute numbers or median and range are given.
Early indicates CR1; Late, > CR1; CP, chronic phase; AP, accelerated phase; BC, blast crisis; TBI, total body irradiation; CsA, cyclosporine; MTX, methotrexate; MMF, mycomofetilphenolate; and Pred, prednisolone.